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Background and purpose of the study: Glimepiride (GLM) was chosen as a model substrate in order to
determine the kinetic parameters for in vitro metabolism via human liver micrososmes (HLM). We aimed to
optimize the turnover of the substrate by the test system in relation to incubation time and HLM concentration in
such a way that it was linearly dependent on time and less than 20% of the substrate was consumed which utilized
the lowest amount of the HLM. Further we aimed to report Km and Vmax values for GLM.
Methods: Linearity of enzyme reactions in microsomal incubations was assessed by monitoring the effect of
incubation time (from 5 to 60 min) and HLM concentration (from 0.2 to 0.75 mg/ml) on metabolite formation of
GLM. The ideal conditions for turnover of GLM were justified using 3x3 factorial design. F value was calculated to
confirm the omission of insignificant terms from the full-model to derive a reduced- model polynomial equation.
The regression equation was used to develop a contour plot that showed turnover rate within the limits of this
design. The optimized reaction velocity data was extrapolated to carry out the kinetic studies in vitro to generate a
saturation curve for the determination of Km and Vmax values.
Results: The reaction was found to be linear with respect to both incubation time between 24 and 50 min and
HLM concentration between 0.3 to 0.65 mg/ml. The Km and Vmax values obtained by nonlinear least squares
regression method was found to be 28.9 ± 2.97 μMole and 0.559 ± 0.017 μMole respectively. Lineweaver-Burk plot
was also used to estimate Km and Vmax which yield value of 29.411 ± 1.25 μMole and 0.571 ± 0.020 μMole/min/mg
protein respectively.
Major conclusion: The statistical approach successfully allows for the optimization of reaction time course
experiments. The results obtained with linear as well as the nonlinear transformation were found to be in close
agreement with each other which shows the best precision for estimates of Km and Vmax.
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For most drugs, biotransformation is the major route of
elimination, and oxidative metabolism by cytochrome
P450 (CYP450) enzymes is a common metabolic pathway
[1]. More than 90% of oxidative metabolic reactions
(phase I) of drugs are catalyzed by enzymes of the
CYP450 family present in liver [2]. In order to investigate
drug metabolism prior to human exposure, there are a
number of options ranging from in vitro screening with
human enzymes to in vivo assessment in experimental
animals. Although animal models can provide information
about the biochemical potential for drug biotransform-
ation (i.e. identifying the metabolite(s) that can be
formed), such models may only indicate what is biologic-
ally possible, not what is biologically relevant for human
drug exposure? This is due to the well documented inter-
species differences in both expression and substrate speci-
ficity of drug metabolizing enzyme. Thus human tissue
systems called as human liver microsomes have been
developed to address the limitations of animal models of
drug metabolism [3,4]. The Pharmaceutical Research and
Manufacturers of America Perspective (PhRMA) and U.S.
Food and Drug Administration (USFDA) guidelines ad-
dress the specific designs of the studies, to define a min-
imal best practice for in vitro and in vivo pharmacokinetic
studies targeted to the development [5,6].
Determinations of the initial velocity conditions are
important for the accurate investigation of enzyme kin-
etic parameters. To determine the kinetic parameters
for CYP450 substrate metabolism, the turnover of the
substrate by the test system needs to be optimized such
that it is linearly dependent on time and less than 20%
of the substrate is consumed. Also it is desirable to
utilize the lowest amount of enzyme in the incubation
that yields readily quantifiable metabolite concentra-
tions. A concentration of below 0.5 mg/ml microsomal
protein is suggested as the low enzyme concentration
would help maintain minimal enzyme binding. The ini-
tial rates of drug disappearance in in vitro metabolism
are to be measured for minimizing any discrepancy
caused by the difference in drug concentrations at the
start and at the time of measurement [7]. Once the ini-
tial velocity conditions have been established, the sub-
strate concentration should be varied to generate a
saturation curve for the determination of Km (substrate
affinity of the enzyme) and Vmax (maximum reaction
rate) values.
To evolve an ideal incubation condition it is import-
ant to understand the complexity of enzymatic reac-
tions in a more systematic way using established
statistical tools such as full factorial design. Thus the
usual approach was to start with a screening design
including all controllable factors that may possibly in-
fluence the experiment, identify the most importantones and proceed with a 3X3 experimental optimization
design [8,9].
GLM belongs to second generation sulphonylurea
which is being used for the treatment of non-insulin
dependent diabetes mellitus (NIDDM), to achieve ap-
propriate control of blood glucose level. In addition, it
maintains a better physiological regulation of insulin
secretion than other sulphonylurea during physical ex-
ercise. GLM has been shown to undergo hepatic oxida-
tive biotransformation via CYP450 system and its
metabolism also has been reported using CYP specific
species of seven CYP2C9 variants found in Japanese
subjects [10-12].
Liquid chromatography with ultraviolet (LC/UV)
[13,14], fluorescence [15,16] or mass spectrometry (MS)
detection [17,18] has been commonly used for quantita-
tive determination of CYP probe substrates. LC/MS has
the advantages of high sensitivity, selectivity and speed.
However, LC/MS instrumentation is costly and may not
be available for routine analysis in every research labora-
tory. In addition, the LC/MS-based assays often require
the use of different ionization and ion detection modes
due to the diverse structure of CYP probe substrate,
which creates difficulty and complexity in developing
LC/MS methods for simultaneous analysis. Fluorescence
and UV are conventional and inexpensive detectors for
LC. Fluorescence detectors are very sensitive but re-
spond only to the few analytes that fluoresce. In con-
trast, many compounds can absorb ultraviolet light.
Therefore, LC with UV detection can be used for the
analysis of CYP probe substrates and metabolites [19].
The drawback of UV detection is its relatively low sensi-
tivity and selectivity. However, our preliminary results
show that the sensitivity of LC/UV is sufficient for the
detection of GLM oxidative biotransformation resulting
from normal microsomal incubations.
The present investigation justifies using GLM as a
model substrate to statistically optimize its oxidative bio-




GLM was received as a gift sample from Cadila Health-
care Ltd., Ahmedabad, India. Nicotinamide Adenine Di-
nucleotide Phosphate, reduced tetra sodium salt
(NADPH), Magnesium chloride (MgCl2) was purchased
from Himedia laboratories, India. Ethylene diamine tetra
acetic acid (EDTA), dipotassium hydrogen phosphate
and potassium dihydrogenphosphate were purchased
from S.d Fine-Chem Limited, India. Methanol and
Acetonitrile of HPLC grade were purchased from Spec-
trochem India. All other chemicals and reagents used in
this study were of analytical grade.
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A pool of the 50 HLM (0.5 ml at 20 mg/ml), mixed gen-
der, in a suspension medium of 250 mM sucrose was
obtained from Xenotech LLC., USA and stored at −80°C
in a deep freezer. The frozen microsomes were thawed
by placing the vial under cold running water and kept in
an ice water bath until use. The total CYP450 content,
protein concentrations, and specific activity of each
CYP450 isoforms were as supplied by the manufacturer.Factorial design and optimization
Based on the results obtained in the preliminary experi-
ments, drug concentration, HLM concentration and incu-
bation time were found to be major variables affecting
metabolism of GLM. Hence 3X3 factorial design was ap-
plied to find the optimized condition for carrying out a
reaction time course experiment for GLM’s oxidative bio-
transformation. In all the experiments NADPH concentra-
tion was 1 mM and buffer concentration was 50 mM. In
this experimental design, GLM in the presence of HLM
was incubated in 27 different combinations.Effect of variables
To study the effect of variables, different batches were
prepared by using 3X3 factorial design. Drug concentra-
tion (X1), incubation time (X2) and HLM concentration
(X3) were selected as three independent variables. The
independent variable and their levels are shown in
Table 1. The turnover rate (Y1%) was taken as a re-
sponse parameter as the dependent variable. These three
factors were evaluated each at 3 levels and experimental
trials were performed for all 27 possible combinations as
reflected from Table 2. The values of the factors were
transformed to allow easy calculation of co-efficient in
polynomial equation. Interactive multiple regression
analysis and F statistics were utilized in order to evaluate
the response. The regression equation for the response
was calculated using the following equation-Response:
Y1ð%Þ ¼ β0 þ β1X1þ β2X2 þ β3X3þ β4X12 þ β5X22 þ
β6X3
2 þ β8X1X2 þ β9X1X3 þ β10X2X3 þ β11X1X2X3
where Y1 (%) is turnover rate and indicates the quanti-
tative effect of the independent variables X1, X2 and
X3, which represent the drug concentration, incubation
time and HLM concentration respectively, β0 is theTable 1 Factors, their levels, and coded values
Levels
Variables Low Medium High
Drug concentration (X1) 10 μmole 20 μmole 30 μmole
Incubation time (X2) 10 min 35 min 60 min
HLM concentration (X3) 0.25 mg/ml 0.5 mg/ml 0.75 mg/ml
Coded values −1 0 +1intercept while β1- β11 represents the regression coeffi-
cient of the system. To identify the significant terms,
the variables having p value > 0.05 in the full model
were discarded and then the reduced model was gener-
ated for the independent variables [20,21].
The multiple regression was applied using Microsoft
excel 2007 in order to deduce the factors having a sig-
nificant effect on the enzymatic reaction and the best fit-
ting mathematical model was selected. Two dimensional
contour plot and three dimensional response surface
plot resulting from the equations were obtained by the
NCSS software.
Incubation conditions
To define the optimal conditions for incubation and
HPLC analysis, GLM (10 – 30 μMole) was incubated
with HLM for 10 to 60 min across a range of micro-
somal enzyme concentrations (0.25 – 0.75 mg/ml).
Briefly the incubation mixtures consisted of 50 mM
phosphate buffer (pH 7.4), 10 mM MgCl2, 1 mM EDTA,
1 mM NADPH and 0.5 mg/ml of microsomal protein. In
all experiments, GLM was dissolved and diluted serially
in methanol and then alcohol was removed by evaporat-
ing to dryness. GLM was reconstituted in potassium
phosphate buffer (50 mM, pH 7.4) .The tubes were
placed into an ice bath and 5 μl of HLM was added and
vortexed. Tubes (duplicate) containing the reaction mix-
ture in phosphate buffer and NADPH solution were
allowed to equilibrate separately in a shaker incubator at
150 rpm for 5 min at 37°C. The reaction was initiated by
adding 20 μl of NADPH immediately to the tubes and
incubation carried out for 30 min. The reaction was ter-
minated by the addition of 100 μl ice cold acetonitrile.
The tubes were centrifuged at 10,000 rpm (4°C; 10 min),
and aliquots of the supernatant were directly injected
into an HPLC system. Control incubations were also
carried out without HLM, NADPH to confirm metabol-
ism. Wherever necessary the volume was made up to
200 μl with buffer.
HPLC analysis
A reported HPLC method with UV detection [22] was
modified to measure GLM in microsomal incubates.
The HPLC system consisted of Shimadzu LC 20 AT
pump and SPD 20A UV detector, a rheodyne 7725 fixed
injector loop (20 μl), Thermo scientific C18 Hypersil
BDS column (4.6 x 250 mm, 5 μm) and a Phenomenex
C18 guard column (4 × 3 mm). The mobile phase was
composed of acetonitrile and 0.1% formic acid (55;
45 v/v). The operating temperature was ambient and
flow rate was 1 ml/min. The column eluent was moni-
tored at a wavelength of 228 nm. Under these chroma-
tographic conditions GLM and its metabolite M1 were
eluted at 3.6 and 9.3 min, respectively.
Table 2 Different batches with their experimental coded level of variables for full factorial design
Batch no. X1 X2 X3 X1
2 X2
2 X3
2 X1X2 X1X3 X2X3 X1X2X3 % Turnover rate ± (SEM)†
1 −1 −1 −1 1 1 1 1 1 1 −1 5.01(0.44)
2 −1 −1 0 1 1 0 1 0 0 0 6.5(0.21)
3 −1 −1 1 1 1 1 1 −1 −1 1 8.9(0.41)
4 −1 0 −1 1 0 1 0 1 0 0 8.92(0.25)
5 −1 0 0 1 0 0 0 0 0 0 19.91(0.69)
6 −1 0 1 1 0 1 0 −1 0 0 18.01(0.48)
7 −1 1 −1 1 1 1 −1 1 −1 1 33.4(0.76)
8 −1 1 0 1 1 0 −1 0 0 0 37.69(0.91)
9 −1 1 1 1 1 1 −1 −1 1 −1 38.81(0.56)
10 0 −1 −1 0 1 1 0 0 1 0 4.4(0.84)
11 0 −1 0 0 1 0 0 0 0 0 6.1(0.58)
12 0 −1 1 0 1 1 0 0 −1 0 8.45(0.76)
13 0 0 −1 0 0 1 0 0 0 0 8.05(0.51)
14 0 0 0 0 0 0 0 0 0 0 18.91(0.62)
15 0 0 1 0 0 1 0 0 0 0 15.05(0.65)
16 0 1 −1 0 1 1 0 0 −1 0 31.75(0.53)
17 0 1 0 0 1 0 0 0 0 0 38.45(1.03)
18 0 1 1 0 1 1 0 0 1 0 38.15(0.89)
19 1 −1 −1 1 1 1 −1 −1 1 1 3.8(0.75)
20 1 −1 0 1 1 0 −1 0 0 0 5.24(0.92)
21 1 −1 1 1 1 1 −1 1 −1 −1 7.91(0.72)
22 1 0 −1 1 0 1 0 0 0 0 7.56(0.55)
23 1 0 0 1 0 0 0 0 0 0 19.08(0.78)
24 1 0 1 1 0 1 0 0 0 0 14.32(0.43)
25 1 1 −1 1 1 1 1 −1 −1 −1 30.56(0.67)
26 1 1 0 1 1 0 1 0 0 0 35.91(0.48)
27 1 1 1 1 1 1 1 1 1 1 36.42(0.34)
†n= 2.
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Preliminary experiments showed that the substrate de-
pletion was linear with respect to both time over 50 min
and liver microsomal protein concentration (0.3-
0.65 mg/ml) at 37°C. Thus a 30 min incubation time and
0.5 mg/ml microsomal protein concentration was
selected. Kinetic studies were performed by incubating
eight concentrations of GLM (0-100 μMole) in duplicate
with HLM.
Determination of Km and Vmax for GLM metabolism by
nonlinear and linear transformations
For the determination of the apparent Michaelis-Menten
constant (Km) and the maximal velocity of the reaction
(Vmax), plots in relation to the substrate concentration
were derived using GraphPad Prism 5 software.
A number of ways of re-arranging the Michaelis-
Menten equation (V = Vmax [S]/Km + [S]) have beendevised to obtain linear relationships which permit more
precise fitting to the experimental points, and estimation
of the values of Km and Vmax. Hence data for reaction
velocities was also evaluated by double reciprocal plot
(Lineweaver-Burk equation, 1/V=Km/Vmax * 1/[S] + 1/
Vmax). The intersection points were determined graphic-
ally using Microsoft Excel 2007.
Data analysis
In the present study, the disappearance of GLM in the
medium incubated at 37°C with HLM in the presence of
the NADPH was determined as the percentage of the ini-
tial amount of GLM in the medium without incubation.
The obtained results were expressed as the turnover rate
in percentage wherever necessary. Substrate disappear-
ance velocity was calculated as [(C0, initial - Cs, t min)/
incubation time/CYP concentration], where C0, initial is
the substrate concentration at time 0 min and Cs, t min
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bation with 0.25, 0.5 and 0.75 mg/ml protein concentra-
tion. Metabolite formation velocity (V) was calculated as
(Cs, t min/incubation time/CYP concentration), where Cs,
tmin was the metabolite concentration after a 10, 35,
60 min incubation.
Results
Reaction linearity optimization by factorial design
Linearity of enzyme reactions in the in vitro human liver
microsomal incubations was assessed by monitoring the ef-
fect of incubation time (from 10 to 60 min) and protein
concentration (from 0.25 – 0.75 mg/ml) on metabolite for-
mation of GLM. Using 3X3 factorial design as shown in
Table 2, 27 batches were prepared varying three independ-
ent variables such as drug concentration (X1), incubation
time (X2) and HLM concentration (X3). The turnover rates
as response are recorded in Table 2. The results of the re-
gression output and response of full model and reduced
model are represented in Table 3. The equations for full
and reduced model are given below.
Full model
Y1ð%Þ ¼ 16:522 0:903X1þ 14:707X2þ 2:891X3
 0:042X12 þ 6:541X22  3:107X32
 0:288X1X2 0:263X1X3
þ 0:468X2X3þ 0:02875X1X2X3 ð1Þ
Reduced model
Y ¼ 16:522þ 14:707X2þ 2:891X3þ 6:541X22
 3:107X32 ð2Þ
As the model was generated by taking only the signifi-
cant terms from the full model, the results are deducedTable 3 Response of Full Model and Reduced Model
Turnover rate (%)
Response Full model Reduced model
X coefficient P value X coefficient P value
X1 −0.903 0.093963003 - -
X2 14.707 2.935912E-15† 14.708 1.92E-19
X3 2.891 3.72138E-05† 2.921 4.63E-06
X12 −0.042 0.962269567 - -
X22 6.541 1.39313E-06† 6.541 9.21E-08
X32 −3.107 0.0027451† −3.107 0.001253
X1X2 −0.288 0.648852013 - -
X1X3 −0.263 0.706627127 - -
X2X3 0.468 0.46193583 - -
X1X2X3 0.028 0.970329444 - -
Intercept 16.522 7.07592E-11 16.49481481 5.84E-15
†significant terms at p > 0.05.by interpreting the reduced model. The positive sign for
coefficient of X2 and X3 in equation 1 shows that the
rate of metabolism increases with increase in incubation
time and HLM concentration.
The results of the Analysis of variance (ANOVA) of
the second order polynomial equation are given in
Table 4. F statistics of the result of ANOVA of full and
reduced model confirmed omission of non-significant
terms of equation 1. Since the calculated F value
(0.6841) was less than the tabled F value (2.74) (α= 0.05,
V1 = 6 and V2= 16), it was concluded that the neglected
terms do not significantly contribute in the prediction
[23]. The goodness of fit of the model was checked by
the determination coefficients (R2). In this case, the
values of the determination coefficients (adj R2) were
very high (>90%), which indicates a high significance of
the model. All the above considerations indicate an ad-
equacy of the regression model [24,25].
Contour plot
Contour plots are a diagrammatic representation of the
values of the response. They are helpful in explaining
the relationship between independent and dependent
variables. The reduced models were used to plot two di-
mension contour plot at a fixed level of 0 for X1 respect-
ively, and the values of X2 and X3 were computed
between −1 and +1 at predetermined values of the turn-
over rate.
Figure 1 shows the contour plot drawn at 0 level of
X1 (20 μMole), for a prefixed turnover rate of GLM
ranging from 4.0% to 34.6%. The plot was found to be
linear for approximate values of 17.60%, 21.00% and
24.40% whereas the approximate values of 10.80%,
14.20% and 17.60% showed somewhat linearly curved
segments. The approximate values 7.40% and 34.60%
showed inconsistent segments signifying nonlinearTable 4 Analysis of variance (ANOVA) for full and
reduced models of GLM metabolism
DF SS MS F† R R2 Adj. R2
Regression
FM 10 4380.932 438.0932 94.570 0.9916 0.9834 0.9730
RM 4 4361.916 1090.479 257.590
Error
FM 16 74.119(E1) 4.632
RM 22 93.134(E2) 4.233
†SSE2-SSE1 = 93.134 – 74.119 = 19.015.
No. of the parameters omitted = 6.
MS of error (full model) =4.632.
F calculated = (SSE2 –SSE1/no. of parameters omitted)/MS of error (full
model) = (19.015/6)/4.632 = 0.684189.
Tabled F value = 2.74 (α= 0.05, V1 = 6 and V2 = 16).
Where DF indicates degrees of freedom; SS sum of square; MS mean sum of



































Figure 1 Contour plot for GLM oxidative biotransformation




















Figure 2 Response surface plot for GLM oxidative
biotransformation showing effect on turnover rate at 0 level
of X1.
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mined from the contour that maximum turnover of
about 34.60% could be obtained with X2 range at 54.4
to 60 min and X3 at 0.4 to 0.8 mg/ml of protein con-
centration. As per the PhRMA and USFDA guidelines,
it was observed that up to 20% metabolism of the sub-
strate within the limits of this design could be obtained
with incubation time (X2) from 24 to 50 min and pro-
tein concentration (X3) from 0.3 to 0.65 mg/ml. Hence
for further study, 0.5 mg/ml protein and 30 min incu-
bation time was optimized.
Response surface plot
Three dimensional response surface plot generated by
NCSS software represented in Figure 2, depicts the turn-
over rate of GLM as a substrate. It shows an increase inFigure 3 Michaelis-Menten plot for GLM oxidative biotransformationturnover of the substrate with increase in the protein
concentration and incubation time.
Determination of Km and Vmax for GLM metabolism by
nonlinear and linear transformations
GLM metabolism in the presence of HLM followed
Michaelis-Menten kinetics. Km and Vmax values obtained
by nonlinear least squares regression method was found
to be 28.9 ± 2.97 μMole and 0.559 ± 0.017 μMole/min/
mg protein respectively. From Lineweaver-Burk plot the
Km and Vmax values were found to be 29.411 ± 1.25
μMole and 0.571 ± 0.020 μMole/min/mg protein respect-
ively (Figure 3). Thus the values obtained with nonlinear
as well as a linear transformation of the data were found
to be in close agreement with each other. Each datain HLM.
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incubations.
Discussion
P450 reaction phenotyping is defined as a set of experi-
ments that aim to define which human cytochrome
P450 enzyme(s) is involved in a given metabolic trans-
formation. Such data are useful in the prediction of
pharmacokinetic drug-drug interactions and interpatient
variability in drug exposure. Any prolonged incubation
in a closed in vitro system such as liver microsomes can
cause formation of metabolites from the primary meta-
bolites of a drug. Inactivation or denaturation of
enzymes can become significant over time in the in vitro
systems. Thus it is of critical importance that initial vel-
ocity conditions are defined [7].
The present study conclusively demonstrates the use
of a 3X3 factorial design in the optimization of initial
velocity conditions affecting turnover of GLM. The
derived reduced polynomial equation, contour plot and
response surface plot aid in predicting the values of
selected independent variables. Contour plot (Figure 1)
obtained by applying a computerized optimization
process suggested a level of 30 min incubation time (X2)
and 0.5 mg/ml protein (X3) as an ideal condition. At this
level the turnover rate (%Y) was found to be ranging
from 18.91% to 19.91%. Thus the rate of GLM dis-
appearance was linear at the chosen concentrations of
substrate using the assay conditions and detection sys-
tem. However, a decrease in the level of incubation time
and protein concentration below the selected level, typ-
ically yield nonlinear initial velocities of enzyme activity.
Once the optimal conditions were obtained, the sub-
strate concentration dependence on the rate of metabol-
ite formation was examined. The Km and Vmax value was
determined by nonlinear regression of a plot of enzyme
activity versus substrate concentration. The Michaelis
constant, Km accounts for the concentration of substrate
at which half the active sites are filled. Thus, Km pro-
vides a measure of the substrate concentration required
for significant catalysis to occur. Vmax is the rate at
which substrate will be converted to product once
bound to the enzyme. A substrate concentration around
or below the Km is ideal for determination of competi-
tive inhibitor activity. Hence further inhibition studies
are needed to confirm the performance of GLM’s oxida-
tive biotransformation in vitro.
Conclusions
This study examines the effects of the main control fac-
tors and attempts to enhance the turnover rate of GLM’s
oxidative biotransformation by optimizing these factors
using full factorial design. It was possible to optimize the
turnover of the candidate drugs within the limits ofdeveloped assay design such that all subsequent in vitro
incubations can be performed using the condition that
ensures linearity with time and HLM concentration, and
less than 20% of the initial substrate is consumed. Thus
the precise information about the effects of each factor
on metabolism can be used to flexibly adjust the system
performance. The best estimates of Km and Vmax values
were obtained with linear as well as nonlinear trans-
formation for the enzymatic assay of GLM under initial
velocity conditions.
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